PMID- 36900181
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230313
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 5
DP  - 2023 Feb 22
TI  - Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of 
      Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.
LID - 10.3390/cancers15051388 [doi]
LID - 1388
AB  - In this prospective study (NCT01595295), 272 patients treated with azacitidine 
      completed 1456 EuroQol 5-Dimension (EQ-5D) questionnaires. Linear mixed-effect 
      modelling was used to incorporate longitudinal data. When compared with a matched 
      reference population, myeloid patients reported more pronounced restrictions in 
      usual activities (+28%, p < 0.0001), anxiety/depression (+21%, p < 0.0001), 
      selfcare (+18%, p < 0.0001) and mobility (+15%, p < 0.0001), as well as lower 
      mean EQ-5D-5L indices (0.81 vs. 0.88, p < 0.0001), and lower self-rated health on 
      the EuroQol Visual Analogue Scale (EQ-VAS) (64 vs. 72%, p < 0.0001). After 
      multivariate-adjustment, (i) the EQ-5D-5L index assessed at azacitidine start the 
      predicted time with clinical benefit (TCB) (9.6 vs. 6.6 months; p = 0.0258; HR = 
      1.43), time to next treatment (TTNT) (12.8 vs. 9.8 months; p = 0.0332; HR = 1.42) 
      and overall survival (OS) (17.9 vs. 12.9 months; p = 0.0143; HR = 1.52); (ii) 
      Level Sum Score (LSS) predicted azacitidine response (p = 0.0160; OR = 0.451) and 
      the EQ-5D-5L index showed a trend (p = 0.0627; OR = 0.522); (iii) up to 1432 
      longitudinally assessed EQ-5D-5L response/clinical parameter pairs revealed 
      significant associations of EQ-5D-5L response parameters with haemoglobin level, 
      transfusion dependence and hematologic improvement. Significant increases of the 
      likelihood ratios were observed after addition of LSS, EQ-VAS or EQ-5D-5L-index 
      to the International Prognostic Scoring System (IPSS) or the revised IPSS 
      (R-IPSS), indicating that they provide added value to these scores.
FAU - Pleyer, Lisa
AU  - Pleyer L
AD  - Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, 
      Austria.
AD  - Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and 
      Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 
      Salzburg, Austria.
AD  - 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, 
      Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, 
      5020 Salzburg, Austria.
FAU - Heibl, Sonja
AU  - Heibl S
AD  - Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, 
      Austria.
AD  - 4th Medical Department of Internal Medicine, Hematology, Internistic Oncology and 
      Palliative Medicine, Klinikum Wels-Grieskirchen GmbH, 4600 Wels, Austria.
FAU - Tinchon, Christoph
AU  - Tinchon C
AD  - Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, 
      Austria.
AD  - Department for Hemato-Oncology, LKH Hochsteiermark, 8700 Leoben, Austria.
FAU - Vallet, Sonia
AU  - Vallet S
AD  - Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, 
      Austria.
AD  - Department of Internal Medicine 2, University Hospital Krems, Karl Landsteiner 
      Private University of Health Sciences, 3500 Krems, Austria.
FAU - Schreder, Martin
AU  - Schreder M
AUID- ORCID: 0000-0002-1699-9715
AD  - Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, 
      Austria.
AD  - 1st Department of Internal Medicine, Center for Oncology and Hematology, Klinik 
      Ottakring, Wiener Gesundheitsverbund, 1030 Vienna, Austria.
FAU - Melchardt, Thomas
AU  - Melchardt T
AD  - Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, 
      Austria.
AD  - Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and 
      Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 
      Salzburg, Austria.
AD  - 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, 
      Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, 
      5020 Salzburg, Austria.
FAU - Stute, Norbert
AU  - Stute N
AD  - Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, 
      Austria.
AD  - Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and 
      Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 
      Salzburg, Austria.
AD  - 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, 
      Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, 
      5020 Salzburg, Austria.
FAU - Fohrenbach Quiroz, Kim Tamara
AU  - Fohrenbach Quiroz KT
AD  - Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and 
      Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 
      Salzburg, Austria.
FAU - Leisch, Michael
AU  - Leisch M
AD  - Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, 
      Austria.
AD  - Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and 
      Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 
      Salzburg, Austria.
AD  - 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, 
      Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, 
      5020 Salzburg, Austria.
FAU - Egle, Alexander
AU  - Egle A
AD  - Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, 
      Austria.
AD  - Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and 
      Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 
      Salzburg, Austria.
AD  - 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, 
      Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, 
      5020 Salzburg, Austria.
FAU - Scagnetti, Lukas
AU  - Scagnetti L
AD  - Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, 
      Austria.
AD  - 4th Medical Department of Internal Medicine, Hematology, Internistic Oncology and 
      Palliative Medicine, Klinikum Wels-Grieskirchen GmbH, 4600 Wels, Austria.
FAU - Wolf, Dominik
AU  - Wolf D
AD  - Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, 
      Austria.
AD  - Department of Internal Medicine V, Innsbruck Medical University, 6020 Innsbruck, 
      Austria.
FAU - Beswick, Richard
AU  - Beswick R
AD  - International Marketing, Swiss Business School, 8302 Zurich, Switzerland.
FAU - Drost, Manuel
AU  - Drost M
AD  - Assign Data Management and Biostatistics GmbH, 6020 Innsbruck, Austria.
FAU - Larcher-Senn, Julian
AU  - Larcher-Senn J
AUID- ORCID: 0000-0003-3169-1900
AD  - Assign Data Management and Biostatistics GmbH, 6020 Innsbruck, Austria.
FAU - Grochtdreis, Thomas
AU  - Grochtdreis T
AUID- ORCID: 0000-0002-0176-7989
AD  - Department of Health Economics and Health Services Research, Hamburg Center for 
      Health Economics, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, 
      Germany.
FAU - Vaisband, Marc
AU  - Vaisband M
AD  - Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, 
      Austria.
AD  - Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and 
      Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 
      Salzburg, Austria.
AD  - Life and Medical Sciences Institute, University of Bonn, 53115 Bonn, Germany.
FAU - Hasenauer, Jan
AU  - Hasenauer J
AD  - Life and Medical Sciences Institute, University of Bonn, 53115 Bonn, Germany.
FAU - Zaborsky, Nadja
AU  - Zaborsky N
AUID- ORCID: 0000-0002-9775-185X
AD  - Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and 
      Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 
      Salzburg, Austria.
AD  - 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, 
      Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, 
      5020 Salzburg, Austria.
AD  - Laboratory of Immunological and Molecular Cancer Research (LIMCR), 5020 Salzburg, 
      Austria.
FAU - Greil, Richard
AU  - Greil R
AUID- ORCID: 0000-0002-4462-3694
AD  - Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, 
      Austria.
AD  - Salzburg Cancer Research Institute (SCRI), Center for Clinical Cancer and 
      Immunology Trials (CCCIT), Austria and Cancer Cluster Salzburg (CCS), 5020 
      Salzburg, Austria.
AD  - 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, 
      Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, 
      5020 Salzburg, Austria.
FAU - Stauder, Reinhard
AU  - Stauder R
AUID- ORCID: 0000-0002-8993-9561
AD  - Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, 
      Austria.
AD  - Department of Internal Medicine V, Innsbruck Medical University, 6020 Innsbruck, 
      Austria.
LA  - eng
PT  - Journal Article
DEP - 20230222
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC10000211
OTO - NOTNLM
OT  - Austrian Registry of Hypomethylating Agents
OT  - EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L)
OT  - acute myeloid leukaemia
OT  - azacitidine
OT  - chronic myelomonocytic leukaemia
OT  - health-related quality of life (HRQoL)
OT  - mixed-effects linear models
OT  - myelodysplastic syndromes
OT  - patient-reported outcome (PRO)
OT  - prognosis
COIS- L.P.: Honoraria from AbbVie, BMS and Novartis; S.H.: Honoraria from AbbVie, AOP, 
      BMS, Janssen Cilag, Novartis and Roche; CT: No potential conflicts of interest; 
      S.V.: Honoraria from Bristol Myers Squibb, Merck, MSD and Pfizer; consultancy 
      fees from Roche, MSD, EUSA Pharma and Merck; Travel support from Pfizer, Roche, 
      Pierre Fabre and Angelini; M.S.: Honoraria and consultancy BMS/Celgene; T.M.: 
      Honoraria from AbbVie and Celgene/BMS; NS: No potential conflicts of interest; 
      K.T.F.Q.: No potential conflicts of interest; M.L.: Honoraria from BMS, Celgene, 
      Gilead, Takeda and Novartis; Travel support: Celgene and Novartis; AE: Honoraria, 
      consultancy and travel support from AbbVie and BMS/Celgene; L.S.: No potential 
      conflicts of interest; D.W.: Research Funding: BMS/Celgene, MSD, Novartis, Pfizer 
      and Roche; Honoraria: BMS/Celgene, GEMOAB, Gilead, Incyte, MSD, Novartis, Pfizer 
      and Roche; R.B.: No potential conflicts of interest; M.D.: No potential conflicts 
      of interest; J.L.-S.: No potential conflicts of interest; T.G.: No potential 
      conflicts of interest; M.V.: No potential conflicts of interest; J.H:. Research 
      Funding: Bohringer-Ingelheim; N.Z.: No potential conflicts of interest; R.G.: 
      Honoraria from AbbVie, Amgen, AstraZeneca, BMS/Celgene, Daiichi Sankyo, Gilead, 
      Merck, Novartis, Roche, Takeda, BMS, MSD, Sandoz and Gilead; Research funding 
      from Celgene, Roche, Merck, Novartis, MSD, Sandoz and Takeda; Consulting: AbbVie, 
      Astra Zeneca, BMS/Celgene, Novartis, Roche, Takeda, Janssen, MSD, Merck, Gilead 
      and Daiichi Sankyo; Travel support from AbbVie, Amgen, Astra Zeneca, BMS/Celgene, 
      Daiichi Sankyo, Gilead, Janssen Cilag, MSD, Novartis and Roche; R.S.: Honoraria 
      from BMS/Celgene. The funders had no role in the design of the study; in the 
      collection, analyses, or interpretation of data; in the writing of the 
      manuscript; or in the decision to publish the results.
EDAT- 2023/03/12 06:00
MHDA- 2023/03/12 06:01
PMCR- 2023/02/22
CRDT- 2023/03/11 01:05
PHST- 2023/01/24 00:00 [received]
PHST- 2023/02/10 00:00 [revised]
PHST- 2023/02/17 00:00 [accepted]
PHST- 2023/03/11 01:05 [entrez]
PHST- 2023/03/12 06:00 [pubmed]
PHST- 2023/03/12 06:01 [medline]
PHST- 2023/02/22 00:00 [pmc-release]
AID - cancers15051388 [pii]
AID - cancers-15-01388 [pii]
AID - 10.3390/cancers15051388 [doi]
PST - epublish
SO  - Cancers (Basel). 2023 Feb 22;15(5):1388. doi: 10.3390/cancers15051388.